PubReading [43] - Click and Cut: a click chemistry approach to developing oxidative DNA damaging agents - N. McStay, A. Kellett et al. episode artwork

EPISODE · Oct 22, 2021 · 59 MIN

PubReading [43] - Click and Cut: a click chemistry approach to developing oxidative DNA damaging agents - N. McStay, A. Kellett et al.

from PubReading

Metallodrugs provide important first-line treatment against various forms of human cancer. To overcome chemotherapeutic resistance and widen treatment possibilities, new agents with improved or alternative modes of action are highly sought after. Here, we present a click chemistry strategy for developing DNA damaging metallodrugs. The approach in- volves the development of a series of polyamine ligands where three primary, secondary or tertiary alkyne-amines were selected and ‘clicked’ using the copper-catalysed azide-alkyne cycloaddition reac- tion to a 1,3,5-azide mesitylene core to produce a family of compounds we call the ‘Tri-Click’ (TC) se- ries. From the isolated library, one dominant ligand (TC1) emerged as a high-affinity copper(II) binding agent with potent DNA recognition and damaging properties. Using a range of in vitro biophysical and molecular techniques––including free radical scavengers, spin trapping antioxidants and base excision repair (BER) enzymes–the oxidative DNA damaging mechanism of copper-bound TC1 was elucidated. This activity was then compared to intracellular results obtained from peripheral blood mononuclear cells exposed to Cu(II)–TC1 where use of BER enzymes and fluorescently modified dNTPs enabled the characterisation and quantification of genomic DNA lesions produced by the complex. The approach can serve as a new avenue for the design of DNA damaging agents with unique activity profiles. - doi.org/10.1093/nar/gkab817 - 2021

NOW PLAYING

PubReading [43] - Click and Cut: a click chemistry approach to developing oxidative DNA damaging agents - N. McStay, A. Kellett et al.

0:00 59:30

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of PubReading?

This episode is 59 minutes long.

When was this PubReading episode published?

This episode was published on October 22, 2021.

What is this episode about?

Metallodrugs provide important first-line treatment against various forms of human cancer. To overcome chemotherapeutic resistance and widen treatment possibilities, new agents with improved or alternative modes of action are highly sought after....

Can I download this PubReading episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!